Analysts Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Price Target at $41.83

Stoke Therapeutics, Inc. (NASDAQ:STOK) has earned an average rating of “Moderate Buy” from the eleven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $41.8333.

Several equities analysts have recently commented on the stock. Chardan Capital reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 18th. Weiss Ratings downgraded shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wall Street Zen downgraded shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Wolfe Research assumed coverage on shares of Stoke Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $40.00 price objective for the company. Finally, Needham & Company LLC upped their price objective on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th.

Insider Activity

In related news, General Counsel Jonathan Allan sold 4,628 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $145,041.52. Following the transaction, the general counsel owned 28,836 shares in the company, valued at $903,720.24. The trade was a 13.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Thomas Leggett sold 2,382 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $74,651.88. Following the transaction, the chief financial officer owned 10,172 shares in the company, valued at $318,790.48. This represents a 18.97% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 69,699 shares of company stock valued at $2,526,714. 9.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Kestra Advisory Services LLC purchased a new position in shares of Stoke Therapeutics during the fourth quarter valued at about $26,000. KBC Group NV purchased a new position in shares of Stoke Therapeutics during the first quarter valued at about $36,000. Harbour Investments Inc. increased its position in shares of Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares during the period. Western Wealth Management LLC purchased a new position in shares of Stoke Therapeutics during the first quarter valued at about $55,000. Finally, Generali Investments Management Co LLC purchased a new position in shares of Stoke Therapeutics during the third quarter valued at about $41,000.

Stoke Therapeutics Trading Up 1.4%

Shares of NASDAQ:STOK opened at $31.45 on Thursday. The company has a market cap of $1.96 billion, a price-to-earnings ratio of -11.19 and a beta of 1.20. The company has a 50-day moving average price of $32.95 and a 200-day moving average price of $32.11. Stoke Therapeutics has a 12 month low of $9.09 and a 12 month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.01. The firm had revenue of $6.23 million during the quarter, compared to the consensus estimate of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. As a group, research analysts forecast that Stoke Therapeutics will post -3.25 EPS for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.